Global pharmaceutical giant Eli Lilly and Company on July 16 announced a $3.8 billion acquisition agreement with AtaiBeckley, a New York City-based clinical-stage biopharmaceutical firm known for its innovative therapeutics in treating mental health conditions.
AtaiBeckley has been developing a series of rapid-acting neuroplastogens, a class of drugs used to treat central nervous system disorders by helping brain cells to reorganize neural connections. These developments include multiple clinical-stage programs and a pipeline of next-generation compounds.
The company’s leading product, BPL-003, also known as mebufotenin benzoate, is being developed for patients with treatment-resistant depression. The medication is a synthetic form of 5-MeO-DMT, a psychedelic drug that is administered through the nasal passages….